0001493152-18-013468.txt : 20180919 0001493152-18-013468.hdr.sgml : 20180919 20180919154351 ACCESSION NUMBER: 0001493152-18-013468 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 38 CONFORMED PERIOD OF REPORT: 20180731 FILED AS OF DATE: 20180919 DATE AS OF CHANGE: 20180919 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Advanced Biomedical Technologies Inc. CENTRAL INDEX KEY: 0001385799 STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842] IRS NUMBER: 980516589 STATE OF INCORPORATION: NV FISCAL YEAR END: 1031 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-53051 FILM NUMBER: 181077740 BUSINESS ADDRESS: STREET 1: 350 FIFTH AVE., 59TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10118 BUSINESS PHONE: (718) 766-7898 MAIL ADDRESS: STREET 1: 350 FIFTH AVE., 59TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10118 FORMER COMPANY: FORMER CONFORMED NAME: Geostar Mineral CORP DATE OF NAME CHANGE: 20070110 10-Q 1 form10-q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

FORM 10-Q

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarter ended July 31, 2018

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission file number 000-53051

Advanced BioMedical Technologies, Inc.

(Exact name of registrant as specified in its charter)

Nevada

(State or other jurisdiction of incorporation or organization)

350 Fifth Avenue, 59th Floor

New York, NY 10118

(Address of principal executive offices, including zip code.)

(718) 766-7898

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES [X] NO [ ]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). YES [X] NO [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a small reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “small reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer [ ]	Accelerated filer [ ]

Non-accelerated filer [ ]	Smaller reporting company [X]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes [ ] No [X]

As of September 19, 2018, there are 69,374,850 shares of common stock outstanding.

All references in this Report on Form 10-Q to the terms “we”, “our”, “us”, the “Company”, “ABMT” and the “Registrant” refer to Advanced BioMedical Technologies, Inc. unless the context indicates another meaning.

TABLE OF CONTENTS

		Page

PART I	FINANCIAL INFORMATION
Item 1.	Financial Statements	3
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	4
Item 3.	Quantitative and Qualitative Disclosures about Market Risk	14
Item 4.	Controls and Procedures	14

PART II	OTHER INFORMATION
Item 1.	Legal Proceedings	15
Item 1A.	Risk Factors	15
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	15
Item 3.	Defaults upon Senior Securities	15
Item 4.	Mine Safety Disclosure	15
Item 5.	Other Information	15
Item 6.	Exhibits	16

PART I – FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

The accompanying condensed consolidated unaudited financial statements of Advanced BioMedical Technologies, Inc., a Nevada corporation are condensed and, therefore, do not include all disclosures normally required by accounting principles generally accepted in the United States of America. These statements should be read in conjunction with the Company’s most recent annual financial statements for the year ended October 31, 2017 included in our Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (“SEC”) on February 13, 2018. In the opinion of management, all adjustments necessary for a fair presentation have been included in the accompanying condensed consolidated financial statements and consist of only normal recurring adjustments. The results of operations presented in the accompanying condensed consolidated financial statements for the period ended July 31, 2018 are not necessarily indicative of the operating results that may be expected for the full year ending October 31, 2018.

ADVANCED BIOMEDICAL TECHNOLOGIES, INC.

AND SUBSIDIARIES

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

AS OF JULY 31, 2018

(UNAUDITED)

ADVANCED BIOMEDICAL TECHNOLOGIES, INC.

AND SUBSIDIARIES

CONTENTS

	Pages

Condensed Consolidated Balance Sheets as of July 31, 2018 (unaudited) and October 31, 2017	F-2

Condensed Consolidated Statements of Operations and Comprehensive Loss for the three months and the nine months ended July 31, 2018 and 2017 (unaudited)	F-3

Condensed Consolidated Statements of Stockholders’ Deficit for the period from October 31, 2017 through July 31, 2018 (unaudited)	F-4

Condensed Consolidated Statements of Cash Flows for the nine months ended July 31, 2018 and 2017 (unaudited)	F-5

Notes to Condensed Consolidated Financial Statements (unaudited)	F-6 – F-10

F-1

ADVANCED BIOMEDICAL TECHNOLOGIES, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

	July 31, 2018			October 31, 2017
	(unaudited)
ASSETS

CURRENT ASSETS
Cash and cash equivalents	$	15,955		$	7,463
Other receivables and prepaid expenses		18,893			17,469
Total Current Assets		34,848			24,932

Property and equipment, cost		488,475			483,482
Less: Accumulated depreciation		(419,070	)		(422,967	)
PROPERTY AND EQUIPMENT, NET		69,405			60,515
LONG-TERM PREPAID EXPENSES, NET		26,721			-
TOTAL ASSETS	$	130,974		$	85,447

LIABILITIES AND STOCKHOLDERS’ DEFICIT

CURRENT LIABILITIES
Other payables and accrued expenses	$	422,812		$	409,079
Due to directors		301,656			321,420
Due to a stockholder		684,365			582,795
Due to related parties		4,212,511			3,767,180
Total Current Liabilities		5,621,344			5,080,474

STOCKHOLDERS’ DEFICIT
Common stock, $0.00001 par value, 100,000,000 shares authorized, 69,374,850 issued and outstanding as of July 31, 2018 and October 31, 2017		694			694
Additional paid-in capital		2,684,923			2,673,620
Accumulated deficit		(8,326,498	)		(7,679,298	)
Accumulated other comprehensive income/(loss)		150,511			9,957
Total Deficit		(5,490,370	)		(4,995,027	)

TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	$	130,974		$	85,447

The accompanying notes are an integral part of these consolidated financial statements

F-2

ADVANCED BIOMEDICAL TECHNOLOGIES, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(UNAUDITED)

	Three months ended						Nine months ended
	July 31, 2018			July 31, 2017			July 31, 2018			July 31, 2017
OPERATING EXPENSES
General and administrative expenses	$	120,799		$	74,308		$	360,769		$	244,169
Depreciation		2,254			4,631			6,771			12,916
Research and development		13,166			7,839			36,892			35,115
Total Operating Expenses		136,219			86,778			404,432			292,200

LOSS FROM OPERATIONS		(136,219	)		(86,778	)		(404,432	)		(292,200	)

OTHER (EXPENSES) INCOME
Interest income		6			15			27			31
Interest paid to a stockholder and related parties		(73,063	)		(57,788	)		(212,902	)		(169,661	)
Interest paid to a third party		-			(3,441	)		-			(8,176	)
Imputed interest		(3,662	)		(3,799	)		(11,303	)		(11,819	)
Other, net		(2,900	)		(18,218	)		(18,590	)		(25,632	)
Total Other (Expenses) Income, net		(79,619	)		(83,231	)		(242,768	)		(215,257	)

LOSS BEFORE TAXES		(215,838	)		(170,009	)		(647,200	)		(507,457	)
Income tax expense		-			-			-			-
NET LOSS		(215,838	)		(170,009	)		(647,200	)		(507,457	)
Net loss attributable to non-controlling interests		-			-			-			-
NET LOSS ATTRIBUTABLE TO ABMT COMMON STOCKHOLDERS		(215,838	)		(170,009	)		(647,200	)		(507,457	)

OTHER COMPREHENSIVE INCOME
Foreign currency translation income		357,674			(101,620	)		140,554			(35,905	)
Total other comprehensive gain/(loss)		357,674			(101,620	)		140,554			(35,905	)
COMPREHENSIVE GAIN/(LOSS) ATTRIBUTABLE TO ABMT COMMON STOCKHOLDERS	$	141,836		$	(271,629	)	$	(506,646	)	$	(543,362	)

Net loss per share-basic and diluted
- basic and diluted	$	(0.00	)	$	(0.00	)	$	(0.01	)	$	(0.01	)

Weighted average number of shares outstanding during the period
- basic and diluted		69,374,850			69,374,850			69,374,850			67,907,818

The accompanying notes are an integral part of these consolidated financial statements

F-3

ADVANCED BIOMEDICAL TECHNOLOGIES, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT (UNAUDITED)

	Common stock				Additional					Accumulated other
	Number				paid-in		Accumulated			comprehensive
	of shares		Amount		capital		deficit			loss			Total
Balance at October 31, 2016		67,124,850	$	671	$	2,520,520	$	(6,987,698	)	$	104,212		$	(4,362,295	)

Stock issued for debt conversion at 0.05 per share		2,000,000		20		99,980		-			-			100,000

Stock issued for services ($0.15 per share)		250,000		3		37,497		-			-			37,500

Imputed interest on advances from directors		-		-		15,623		-			-			15,623

Net loss for the year		-		-		-		(691,600	)		-			(691,600	)

Foreign currency translation loss		-		-		-		-			(94,255	)		(94,255	)

Balance at October 31, 2017		69,374,850	$	694	$	2,673,620	$	(7,679,298	)	$	9,957		$	(4,995,027	)

Imputed interest on advances from directors		-		-		11,303		-			-			11,303

Net loss for the period		-		-		-		(647,200	)		-			(647,200	)

Foreign currency translation loss		-		-		-		-			140,554			140,554

Balance at July 31, 2018		69,374,850	$	694	$	2,684,923	$	(8,326,498	)	$	150,511		$	(5,490,370	)

The accompanying notes are an integral part of these consolidated financial statements

F-4

ADVANCED BIOMEDICAL TECHNOLOGIES, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

	Nine months ended
	July 31,
	2018			2017
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss attributable to ABMT common stockholders	$	(647,200	)	$	(507,457	)
Adjustments to reconcile net loss to cash used in
Depreciation		6,771			12,916
Amortisation of long-term prepaid expenses		4,542			-
Stock issued for services		-			37,500
Imputed interest		11,303			11,819
Changes in operating assets and liabilities
Decrease (increase) in:
Other receivables and prepaid expenses		(1,682	)		1,302
Increase in:
Other payables and accrued expenses		24,588			112,302
Net cash used in operating activities		(601,678	)		(331,618	)

CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property and equipment		(17,686	)		-
Renovation of factory premises		(32,700	)		-
(Increase) decrease in deposit for purchase of property and equipment		-			1,202
Net cash used in investing activities		(50,386	)		1,202

CASH FLOWS FROM FINANCING ACTIVITIES
Due to a stockholder		102,106			71,908
Due to directors		(12,823	)		(40,843	)
Due to related parties		571,636			302,305
Net cash provided by financing activities		660,919			333,370

EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS		(363	)		116

NET INCREASE IN CASH AND CASH EQUIVALENTS		8,492			3,070

CASH AND CASH EQUIVALENTS AT THE BEGINNING OF PERIOD		7,463			6,559

CASH AND CASH EQUIVALENTS AT THE END OF PERIOD	$	15,955		$	9,629

The accompanying notes are an integral part of these consolidated financial statements

F-5

ADVANCED BIOMEDICAL TECHNOLOGIES, INC.

AND SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED

FINANCIAL STATEMENTS (UNAUDITED)

NOTE 1 BASIS OF PRESENTATION

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.

In the opinion of management, the unaudited condensed consolidated financial statements contain adjustments considered necessary to present fairly the Company’s financial position as of July 31, 2018, the consolidated results of operations for the three and nine months ended July 31, 2018 and 2017 and consolidated statements of cash flows for the nine months ended July 31, 2018 and 2017 on an accrual basis and in accordance with accounting principles generally accepted in the United States of America for interim financial information and rules and regulations of the SEC. The consolidated results for the three and nine months ended July 31, 2018 are not necessarily indicative of the results to be expected for the entire fiscal year ending October 31, 2018. These consolidated financial statements should be read in conjunction with the consolidated financial statements and notes for the year ended October 31, 2017 appearing in the Company’s annual report on Form 10-K as filed with the Securities and Exchange Commission on February 13, 2018.

The reporting currency of the Company is US dollar.

NOTE 2 ORGANIZATION

Advanced BioMedical Technologies, Inc. (fka “Geostar Mineral Corporation” or “Geostar”) (“ABMT”) was incorporated in Nevada on September 12, 2006.

Shenzhen Changhua Biomedical Engineering Company Limited (“Shenzhen Changhua”) was incorporated in the People’s Republic of China (“PRC”) on September 25, 2002 as a limited liability company with a registered capital of $724,017. Shenzhen Changhua is owned by two stockholders in the proportion of 70% and 30% respectively. Shenzhen Changhua plans to develop, manufacture and market self-reinforced, re-absorbable degradable PA screws, robs and binding ties for fixation on human fractured bones. The Company is currently conducting clinical trials on its products and intends to raise additional capital to produce and market its products commercially pending the approval from the China Food and Drug Administration (“CFDA”, fka “SFDA”) of the PRC on its products. The Company has no revenue since its inception and, in accordance with Accounting Standards Codification (“ASC”) Topic 915, “Development Stage Entities” (formerly Statement of Financial Accounting Standard (“SFAS”) No. 7, “Accounting and Reporting by Development Stage Enterprise”), is considered a Development Stage Company.

Masterise Holdings Limited (“Masterise”) was incorporated in the British Virgin Islands on May 31, 2007 as an investment holding company and was then owned as to 63% by the spouse of Shenzhen Changhua’s 70% majority stockholder at the time and 37% by a third party corporation.

On January 29, 2008, Masterise entered into a Share Purchase Agreement (“the Agreement”) with a stockholder of Shenzhen Changhua whereupon Masterise acquired 70% of Shenzhen Changhua for US$64,100 in cash. The acquisition was completed on February 25, 2008. As both Masterise and Shenzhen Changhua were under common control and management, the acquisition was accounted for as a reorganization of entities under common control. Accordingly, the operations of Shenzhen Changhua were included in the consolidated financial statements as if the transactions had occurred retroactively.

F-6

On December 31, 2008, ABMT consummated a Share Exchange Agreement (“the Exchange Agreement”) with the stockholders of Masterise pursuant to which ABMT issued 50,000 shares of Common Stock to the stockholders of Masterise for 100% equity interest in Masterise.

Concurrently, on December 31, 2008, a major stockholder of ABMT also consummated an Affiliate Stock Purchase Agreement (the “Affiliate Agreement”) with thirteen individuals including all the stockholders of Masterise, pursuant to which the major stockholder sold a total of 5,001,000 shares of ABMT’s common stock for a total aggregate consideration of $5,000, including 4,438,250 shares to the stockholders of Masterise.

On consummation of the Exchange Agreement and the Affiliate Agreement, the 70% majority stockholder of Masterise became an 80.7% stockholder of ABMT.

On March 13, 2009, the name of the Company was changed from Geostar Mineral Corporation to Advanced Biomedical Technologies, Inc.

The merger of ABMT and Masterise was treated for accounting purposes as a capital transaction and recapitalization by Masterise (“the accounting acquirer”) and a re-organization by ABMT (“the accounting acquiree”). The financial statements have been prepared as if the re-organization had occurred retroactively.

Accordingly, these financial statements include the following:

	(1)	The balance sheet consisting of the net assets of the acquirer at historical cost and the net assets of the acquiree at historical cost.

	(2)	The statement of operations including the operations of the acquirer for the periods presented and the operations of the acquiree from the date of the transaction.

ABMT, Masterise and Shenzhen Changhua are hereinafter referred to as (“the Company”).

NOTE 3 PRINCIPLES OF CONSOLIDATION

The accompanying condensed consolidated financial statements include the financial statements of ABMT and its wholly owned subsidiaries, Masterise and its 70% owned subsidiary, Shenzhen Changhua. The non-controlling interests in periods prior to 2012 represent the non-controlling stockholders’ 30% proportionate share of the results of Shenzhen Changhua.

All significant inter-company balances and transactions have been eliminated in consolidation.

NOTE 4 USE OF ESTIMATES

The preparation of the financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

NOTE 5 RELATED PARTY TRANSACTIONS

As of July 31, 2018 and October 31, 2017, the Company owed a stockholder $684,365 and $582,795 respectively which are unsecured and repayable on demand. Interests are charged at 7% per annum on the amount owed.

As of July 31, 2018 and October 31, 2017, the Company owed four related parties a total of $4,212,511 and $3,767,180 respectively which are unsecured and repayable on demand. Interests are charged at 7% per annum on the amounts owed.

F-7

Total interest expenses on advances from a stockholder and the related parties accrued for the three and nine months ended July 31, 2018 and 2017 were $73,063, $57,788, $212,902, and $169,661 respectively.

As of July 31, 2018 and October 31, 2017, the Company owed $301,656 and $321,420 respectively, to two directors for advances made on an unsecured basis, repayable on demand and interest free.

Imputed interest charged at 5% per annum on the amounts owed to two directors is $3,662, $3,799, $11,303 and $11,819 for the three and nine months ended July 31, 2018 and 2017 respectively.

NOTE 6 COMMITMENTS AND CONTINGENCIES

The Company’s existing rental leases do not contain significant restrictive provisions. The schedule of future minimum lease obligations falling due under non-cancelable rental operating leases is as follows:

Fiscal year ending October 31,
2018		3,527
2019		7,055

Total	$	10,582

NOTE 7 FAIR VALUE OF FINANCIAL INSTRUMENTS

The Financial Accounting Standards Board (FASB) Codification Topic 825 (ASC Topic 825), “Disclosure About Fair Value of Financial Instruments,” requires certain disclosures regarding the fair value of financial instruments. The carrying amounts of other receivables and prepaid expenses, other payables and accrued liabilities and due to a stockholder, directors and related parties approximate their fair values because of the short-term nature of the instruments. The management of the Company is of the opinion that the Company is not exposed to significant interest or credit risks arising from these financial statements.

NOTE 8 RECENT ACCOUNTING PRONOUNCEMENTS

Business Combination: Clarifying the Definition of a Business

In January 2017, the FASB issued ASU No. 2017-1 “Topic 805, Business Combinations: Clarifying the Definition of a Business”. The amendments in this update provide a screen to determine when a set is not a business. The screen requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business. This screen reduces the number of transactions that need to be further evaluated. The amendments in this update affect all reporting entities that must determine whether they have acquired or sold a business. Public business entities should apply the amendments in this update to annual periods beginning after December 15, 2017, including interim periods within those periods. All other entities should apply the amendments to annual periods beginning after December 15, 2018, and interim periods within annual periods beginning after December 15, 2019. The Company does not expect the adoption of ASU 2017-1 to have a material impact on its consolidated financial statements.

Simplifying the Test for Goodwill Impairment

In January 2017, the FASB issued ASU No. 2017-4 “Topic 350: Intangibles-Goodwill and Other: Simplifying the Test for Goodwill Impairment.” The amendments in this update eliminate step two of the goodwill impairment test and specifies that goodwill impairment should be measured by comparing the fair value of a reporting unit with its carrying amount. Additionally, the amount of goodwill allocated to each reporting unit with a zero or negative carrying amount of net assets should be disclosed. The amendments in this update are effective for annual or interim goodwill impairment tests performed in fiscal years beginning after December 15, 2019; early adoption is permitted. The Company does not expect the adoption of ASU 2017-4 to have a material impact on its consolidated financial statements.

F-8

Share-based Compensation

In May 2017, the FASB issued guidance on changes to terms and conditions of share-based payment awards. The amendment provides guidance about which changes to terms or conditions of a share-based payment award require an entity to apply modification accounting. The guidance is effective for the fiscal year beginning on January 1, 2018, including interim periods within that year.

In June 2018, the scope of Topic 718 has been expanded to include sharebased payment transactions for acquiring goods and services from nonemployees. An entity should apply the requirements of Topic 718 to nonemployee awards except for specific guidance on inputs to an option pricing model and the attribution of cost (that is, the period of time over which share-based payment awards vest and the pattern of cost recognition over that period). The amendments specify that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. The amendments also clarify that Topic 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under Topic 606, Revenue from Contracts with Customers. The amendments in this Update are effective for public business entities for fiscal years beginning after December 15, 2018 and after December 15, 2019 for all other entities. Early adoption is permitted, but no earlier than an entity’s adoption date of Topic 606.

The Company does not anticipate that adoption of these guidances will have a material impact on its consolidated financial statements.

Revenue Recognition

In May 2014, the FASB issued guidance on revenue from contracts with customers that will supersede most current revenue recognition guidance, including industry-specific guidance. Under the new standard, a good or service is transferred to the customer when (or as) the customer obtains control of the good or service, which differs from the risk and rewards approach under current guidance. The guidance provides a five-step analysis of transactions to determine when and how revenue is recognized. Other major provisions include capitalization of certain contract costs, consideration of the time value of money in the transaction price and allowing estimates of variable consideration to be recognized before contingencies are resolved in certain circumstances. The guidance also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from an entity’s contracts with customers. In March, April and May 2016, the FASB issued three additional updates regarding identifying performance obligations and licensing, certain principal versus agent considerations and various narrow scope improvements based on practical questions raised by users. In September 2017, the FASB issued additional amendments providing clarification and implementation guidance. The guidance may be adopted through either retrospective application to all periods presented in the financial statements (full retrospective approach) or through a cumulative effect adjustment to retained earnings at the effective date (modified retrospective approach). The guidance is effective for the fiscal periods beginning on January 1, 2018.

Leases

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) (“ASU 2016-02”), which modifies lease accounting for lessees to increase transparency and comparability by recording lease assets and liabilities for operating leases and disclosing key information about leasing arrangements. The new standard, as amended by ASU 2018-01 and ASU 2018-11, is effective for annual periods beginning after December 15, 2018 on a modified retrospective basis. The Company will adopt ASU 2016-02 in its first quarter of the year ending October 31 2020. The Company expects its leases designated as operating leases in Note 6, “Commitments and Contingencies,” will be reported on the consolidated balance sheets upon adoption. However, the ultimate impact of adopting ASU 2016-02 will depend on the lease terms as of the adoption date.

The Company has reviewed all recently issued, but not yet effective, accounting pronouncements and do not believe the future adoptions of any such pronouncements may be expected to cause a material impact on the financial condition or the results of operations.

F-9

NOTE 9 GOING CONCERN

As reflected in the accompanying unaudited condensed consolidated financial statements, the Company has not commenced revenue producing operations and has an accumulated deficit of $8,326,498 as of July 31, 2018 and which includes a net loss of $647,200 for the nine months ended July 31, 2018. As of July 31, 2018, the Company’s total current liabilities exceeded its total current assets by $5,586,496 and the Company used cash in operations of $601,678 for the nine months ended on that date. These factors raise substantial doubt about its ability to continue as a going concern. In view of the matters described above, recoverability of a major portion of the recorded asset amounts shown in the accompanying condensed consolidated balance sheet is dependent upon continued operations of the Company, which in turn is dependent upon the Company’s ability to raise additional capital, obtain financing and succeed in its future operations. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Management has taken the following steps to revise its operating and financial requirements, which it believes are sufficient to provide the Company with the ability to continue as a going concern. The Company is actively pursuing additional funding and strategic partners, which will enable the Company to implement its business plan. Management believes that these actions as successful will allow the Company to continue its operations through the next fiscal year.

F-10

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Forward Looking Statements

This section of the report includes a number of forward-looking statements that reflect our current views with respect to future events and financial performance. Forward-looking statements are often identified by words like: believe, expect, estimate, anticipate, intend, project and similar expressions, or words which, by their nature, refer to future events. Actual results could differ materially from those anticipated in these forward looking statements as a result of any number of factors, including those set forth in this Quarterly Report, and in the Company’s most recent Annual Report on Form 10-K filed on February 13, 2018.

All written and oral forward-looking statements made in connection with this Quarterly Report on Form 10-Q that are attributable to us or persons acting on our behalf are expressly qualified in their entirety by these cautionary statements. Given the uncertainties that surround such statements, you are cautioned not to place undue reliance on such forward-looking statements, which apply only as of the date of this quarterly report. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from historical results or our predictions.

Overview

The following discussion is an overview of the important factors that management focuses on in evaluating our businesses, financial condition and operating performance and should be read in conjunction with the financial statements included in this Quarterly Report on Form 10-Q.

The Company is subject to a number of risks similar to other companies in the medical device industry. These risks include but are not limited to rapid technological change, uncertainty of market acceptance of our products, uncertainty of regulatory approval, competition from substitute products and larger companies, the need to obtain additional financing, compliance with government regulation, protection of proprietary technology, product liability, and the dependence on key individuals.

Our Business

We are engaged in the business of designing, developing, manufacturing and marketing of biomaterial internal fixation devices. We hold one medical device permit from the China Food and Drug Administration (“CFDA”) for our product - polymer orthopaedic internal fixation screws and two patents issued by the State Intellectual Property Office of the P.R.C. (“SIPO”). Our polyamide materials, their uses and manufacturing processes are protected by Patent No. ZL971190739. A new patent, No. ZL201410647464.1 titled “Bone Fracture Plate Made of High Polymer Materials” was granted to us in January 2018. Our polyamide materials are used in producing screws, binding wires, rods and related products. These products are used in a variety of applications including orthopedic trauma, sports related medical treatment, or cartilage injuries, and reconstructive dental procedures. At this time, our company is the sole patent holder and market permit holder of PA technologies in China, as well as the only company currently engaged in clinical trials, manufacturing and marketing for PA orthopaedic internal fixation devices in the PRC. Our products are made of a very unique material called PA6-P(MMA-CO-NVP)-HA (“PA”). Our PA products, such as screws, binding wires, rods, suture anchors and rib-pins consist of enhanced fibers and high molecular polymers which are designed to facilitate quick healing of complex fractures in many areas of the human skeletal system.

Our products offer a number of significant advantages over existing metal implants and the first generation of degradable implants (i.e. PLLA) for patients, surgeons and other customers including:

	1.	A notably reduced need for a secondary surgery to remove implant due to post-operative complications, therefore avoiding unnecessary risk and expense on all patient care;
	2.	Enhancing the performance of the materials by manufacturing them to be easily fitted to each patient, forming an exact fit;
	3.	Improving the biological activity of materials. Clinical trial results have shown that PA implants promote a progressive shift of load to the new bone creating micro-motion and thereby avoiding bone atrophy due to ‘stress shielding’;
	4.	Reducing the chance of post-operative infection;
	5.	Stimulate bone tissues to facilitate effective biological integration, benefitting the regeneration of bone;
	6.	Ease of post-operative care i.e. no distortion during x-ray imaging;
	7.	Simple and cost-effective to manufacture.

Our products are designed to replace the traditional internal fixation device made of stainless steel and titanium and overcome the limitations of previous generations of products such as PLA and PLLA. Our laboratory statistics show that our PA products have a higher mechanical strength, last longer in degradation ratio and are more evenly absorbed form outer layer inwards as compared with similar materials such as PLA and PLLA. Thus PA allows increased restoration time for bone healing and re-growth. The Company’s polymer orthopaedic internal fixation screws received approval from the China Food and Drug Administration (“CFDA”) in April 2018.

CFDA Application Process and Approval for PA Screws

The Company first submitted its application for PA Screws to the CFDA in 2008. The application has been withheld by the CFDA pending additional clinical trial cases. This is due to the amended CFDA regulations, which unlike previous regulations require the applicant to specify the position on the body where the clinical trial is carried out. Our amended CFDA application has specified the ankle fracture as the body part of our clinical trial. This is because bones around this part carry most of the body weight.

Due to the uniqueness of our material, there were no established CFDA Product Standards that we could follow during our application process for our PA Screws. To establish our own Product Standards, the Company had been carrying out extra tests. The Company submitted its Product Standards and supplementary reports to the CFDA in 2014. In December 2016, the Company received a notice from the CFDA requesting supplementary report as part of the review process. The Company completed the supplementary report and submitted it to the CFDA in June 2017.

In April 2018, the Company’s application for its PA Screws was approved by the CFDA in China (Medical Device Certification Number: 20183460133).

Process of Human Trials

As of July 31, 2018, for medical study and comparison purpose, the Company has completed a total of 83 successful clinical human trial cases, including 71 cases on ankle fractures and 57 successful PA Binding Wire trial cases. We have been conducting human trials at the 6 state level hospitals recognized by CFDA for clinical trials in different cities throughout China; including Nanchang, Changsha, Luoyang, Nanning and Tianjin. The cities and provinces where our clinical trial hospitals are based will be the initial target regions on our marketing plan. These regions are both densely populated and have experienced high or above medium economic growth. The clinical trials for the Company’s PA Screws have been completed with 100 percent success rate. Having gained CFDA approval for PA Screws, the Company is planning to start clinical trials on series of orthopaedic products the Company has developed using the same unique biomaterial.

Government Regulation

Medical implant devices/products manufactured or marketed by the Company in China are subject to extensive regulations by the CFDA. Pursuant to the related laws and acts, as amended, and the regulations promulgated there under (the “CFDA Regulations”), the CFDA regulates the clinical testing, manufacture, labeling, distribution and promotion of medical devices. The CFDA also has the authority to request repair, replacement, or refund of the cost of any device manufactured or distributed by the Company.

Under the CFDA Regulations, medical devices are classified into three classes (class I, II or III), the basis of the controls deemed necessary by the CFDA to reasonably assure their safety and efficacy. Under the CFDA’s regulations, class I devices are subject to general controls (for example, labeling and adherence to Good Manufacturing Practices (“GMP”) requirements) and class II devices are subject to general and special controls. Generally, class III devices are those which must receive premarket approval by the CFDA to ensure their safety and efficacy (for example, life-sustaining, life-supporting and certain implantable devices, or new devices which have not been found substantially equivalent to legally marketed class I or class II devices). The Company is classified as a manufacturer of class III medical devices. Current CFDA enforcement policy prohibits the marketing of approved medical devices for unapproved uses.

Before a new device can be introduced into the market in China, the manufacturer generally must obtain CFDA marketing clearance through clinical trials. Since the Company is classified as a manufacturer of Class III medical devices, the Company must carry out all clinical trials in pre-selected CFDA approved hospitals.

Manufacturers of medical devices for marketing in China are required to adhere to GMP requirements. Enforcement of GMP requirements has increased significantly in the last several years and the CFDA has publicly stated that compliance will be more strictly scrutinized. From time to time the CFDA has made changes to the GMP and other requirements that increase the cost of compliance. Changes in existing laws or requirements or adoption of new laws or requirements could have a material adverse effect on the Company’s business, financial condition and results of operations. There can be no assurance that the Company will not incur significant costs to comply with applicable laws and requirements in the future or that applicable laws and requirements will not have a material adverse effect upon the Company’s business, financial condition and results of operations.

Regulations regarding the development, manufacturing and sale of the Company’s products are subject to change. The Company cannot predict the impact, if any, that such changes might have on its business, financial condition and results of operations.

Results of Operations

The “Results of Operations” discussed in this section merely reflect the nine and three months ended July 31, 2018 and 2017:

Nine Months Ended July 31, 2018 and 2017

Revenue

The Company did not have revenue for both of nine months ended July 31, 2018 and 2017.

Cost of Goods Sold

The Company did not have cost of goods sold for both of nine months ended July 31, 2018 and 2017.

Operating Expenses

The operating expenses for the nine months ended July 31, 2018 and 2017 was $404,432 and $292,200. Compare to 2017, 2018 was increased by $112,232 or 38.41%. This increment was a result of $116,600 increase in general and administrative expenses. The depreciation and research and development expenses did not have significant changes.

Income (Loss) from Operations

Since the Company did not have revenue or cost of goods sold, the operating expenses were equal to the net loss from operations. Details of changes were same as operating expenses.

Other Income (expenses)

Other expenses for the nine months ended July 31, 2018 and 2017 was $242,768 and $215,257. Compare to 2017, 2018 was increased by $27,511 or 12.78%.The major changes were the increase of $43,241 in interest paid to stockholder and related parties and offset with reduction of $8,176 in interest paid to third party and $7,042 in other expenses. Other items had no significant changes.

Net Income (Loss)

Net loss for the nine months ended July 31, 2018 and 2017 was $647,200 and $507,457. Compare to 2017, 2018 was increased by $139,743 or 27.54%.The major changes were the increase of $112,232 in operating expenses and the increase of $27,511 in other expenses. Since the Company did not have revenue or cost of goods sold, the net loss changes were reflected by the changes in operating expenses and other expenses.

Three Months Ended July 31, 2018 and 2017

Revenue

The Company did not have revenue for both of three months ended July 31, 2018 and 2017.

Cost of Goods Sold

The Company did not have cost of goods sold for both of three months ended July 31, 2018 and 2017.

Operating Expenses

The operating expenses for the three months ended July 31, 2018 and 2017 was $136,219 and $86,778. Compare to 2017, 2018 was increased by $49,441 or 56.97%. This increment was a result of $46,491 increase in general and administrative expenses. The depreciation and research and development expenses did not have significant changes.

Income (Loss) from Operations

Since the Company did not have revenue or cost of goods sold, the operating expenses were equal to the net loss from operations. Details of changes were same as operating expenses.

Other Income (expenses)

Other expenses for the three months ended July 31, 2018 and 2017 was $79,619 and $83,231. Compare to 2017, 2018 was decreased by $3,612 or 4.34%.The major changes were the increase of $15,257 in interest paid to stockholder and related parties and offset with reduction of $3,441 in interest paid to third party and $15,318 in other expenses. Other items had no significant changes.

Net Income (Loss)

Net loss for the three months ended July 31, 2018 and 2017 was $215,838 and $170,009. Compare to 2017, 2018 was increased by $45,829 or 26.95%.The major changes were the increase of $49,441 in operating expenses and offset by the reduction of $3,612 in other expenses. Since the Company did not have revenue or cost of goods sold, the net loss changes were reflected by the changes in operating expenses and other expenses.

The information and results of the Company for the period from September 25, 2002 (Shenzhen Changhua’s date of inception) to July 31, 2018 and 2017 are discussed in details as following:

Revenues

The Company received market permit for one of its product in China in April 2018 and is in its early marketing stage. The Company does not have any revenue and is expecting its first revenue from sales of its product in Q4 2018. The management team is continuously looking for fundraising possibilities for product improvement, machinery upgrades, facility expansions, continuous research and development, and sales and marketing.

Our facility is located in Shenzhen China, which is built to meet the GMP standards. Our facility covers about 865 square meters, which includes the combined facilities of offices, laboratories, and workshops. There is one production line for the PA Screw and another production line for the PA Binding Wire. The annual production capabilities of each production line are 100,000 pieces for PA Screw, and 240,000 packs for the PA Binding Wires. Both production lines, at their maximum production capacity, are capable of generating approximately $32,000,000 in annual revenue.

Estimate current production lines in full capacity
	Output Quantity (Max.)			Price at ex-factory ($)			Total Turnover ($)
PA Screw		100,000	(piece)		200			20,000,000
PA Binding Wire		240,000	(pack)		50			12,000,000
						Total:		32,000,000

The Company will market its products through a hybrid sales force comprised of a managed network of independent regional distributors/sales agents (80%) and direct sales representatives (20%) in China.

There are two ways the Company will generate revenue, 1) through our nationwide and regional distributors and 2) through our direct sales channels.

China’s Marketing Analysis and Sales Strategy:

We have established long term relationships with many hospitals and national distributors in China. Ms. Hui Wang, the Company’s CEO, has over 25 years’ sales experience in medical distribution. She will be in charge of our sales programs. Professor Shangli Liu, our chief medical advisor, is one of the highest ranked orthopedic doctors in China as well as being highly renowned in the rest of the world. He will assist the Company in nationwide product promotion and joint projects with associated academic institutions and medical schools.

During product development and clinical trial stages, we developed close relationships with many major national hospitals. We expect these relationships to boost our revenue generation following CFDA final approval..

China’s market for PA devices depends on 3 major conditions:

- Patients

- Advanced technology level

- Performance and price of the materials

The demand for internal fixation medical devices has rapidly increased during the last decade. According to China Health Care Year Book 2013, the total revenue of Chinese orthopaedic hospitals in 2013 was US$1.28 billion with over 11.5 million patients. From 2009 to 2013, the market size of China’s orthopaedic devices has grown from US$1.1 billion to US$1.92 billion, and it is estimated to reach US$4 billion in 2020. China has overtaken Japan as the second largest market in the world. The Chinese market size for trauma treatment implant devices such as our PA Screw and PA Wire was US$1.88 billion in 2013 and US$2.12 billion in 2014 with a growth rate of 12.7%, it is estimated to grow to US$3.02 billion in 2017 and reach US$3.17 billion in 2018 with a growth rate of 11.6%9. (Source: Shenwan Hongyuan Securities research report).

The Company has advantages and more opportunities over other competitors due to:

- We are the only company received approval for our unique PA biomaterial by CFDA in China.

- No other similar patent registrations in China.

- We are the only company qualified and permitted to perform PA clinical trials by CFDA to the best of our knowledge.

- We have a timing advantage over other companies in China which would have to go through the preclinical testing for the CFDA permit on clinical trials.

- Under existing regulations by CFDA, it will take at least 3-5 years for clinical trials of new materials.

Number of Hospitals at the end of June 2018 Statistic and Census report by the National Health and Family Planning Commission of the People’s Republic of China.

Statistic and Census report by National Health and Family Planning Commission of the People’s Republic of China
(June 2018)

	June 2018		June 2017		Increase / (Decrease)
Total No. of Hospitals		31,710		29,719		1,991
Public Hospital		12,121		12,566		(445	)
Private Hospital		19,589		17,153		2,436
Hospital Rating
AAA		2,439		2,286		153
AA		8,569		8,118		451
A		10,210		9,461		749

In general, technological advancements and the marketing potential within Asia are the biggest factors in driving significant growth within the global orthopedic devices market. Another major factor that positively influences this market is the growing number of aging baby boomers with active lifestyles. This sector represents a large portion of the total population.

Research and Development

The Company has developed five proprietary polymer fixation implant product lines, including screws, pins, tacks, rods and binding wires, which provide an alternative to metal implants and overcome the limitations of first generation polymer fixation devices. The Company’s product range will ultimately cover the full gamut of components featuring PA macromolecule polymer materials for implantation, including human orthopaedic and dental applications, as well as veterinary applications. We expect research and development expenses to grow as we continue to invest in basic and advanced research, clinical trials, product development and in our intellectual property.

Although there are substantial research and development (R&D) activities within the Company and, the Company regards R&D activity as the key to maintain its technological advantage and innovation, there can be no assurance that the Company will be able to obtain any further clearances or approvals, if required, to market its products for their intended uses on a timely basis, if at all. Moreover, regulatory approvals, if granted, may include significant limitations on the indicated uses for which a product may be marketed. Delays in the receipt of or the failure to obtain such clearances or approvals, the need for additional clearances or approvals, the loss of previously received clearances or approvals, unfavorable limitations or conditions of approval, or the failure to comply with existing or future regulatory requirements could have a material adverse effect on the Company’s business, financial condition and results of operations.

Pre-Market Research

The Company has been conducting Pre-Market Research before its PA Screws application was approved by the CFDA in April 2018. The research is intended to estimate the potential market success of the company’s products that can be expected. The research also beyond the Company’s initial market - China, and covers international markets. Based on the results of our Pre-Market Research and the positive feedbacks we have received from trade shows and industrial conferences, it is the Company’s intention to apply for additional international regulatory approvals in due course.

Finance Costs

As of July 31, 2018 and October 31, 2017, a stockholder and four related parties had loaned a total of $4,896,876 and $4,349,975 respectively to the Company as unsecured loans repayable on demand and interest is charged at 7% per annum on the amount due. Total interest expenses on advances from a stockholder and the related parties accrued for the three and nine months ended July 31, 2018 and 2017 were $73,063, $57,788, $212,902 and $169,661 respectively.

As of July 31, 2018 and October 31, 2017, the Company owed $301,656 and $321,420 respectively to the directors for advances made on an unsecured basis, repayable on demand. Total imputed interest expenses on advances from the directors, calculated at 5% per annum, recorded as additional paid-in capital amounted to $3,662, $3,799, $11,303 and $11,819 for the three and nine months ended July 31, 2018 and 2017 respectively.

Net Loss

The net loss attributable to common stockholders for the three and nine months ended July 31, 2018 and 2017 were $215,838, $170,009, $647,200 and $507,457 respectively. We do not have any revenue from inception to July 31, 2018 but have to incur operating expenses for the upkeep of the Company and the clinical trials.

Liquidity and Capital Resources

We had a working capital deficit of $5,586,496 and $5,055,542 as of July 31, 2018 and October 31, 2017 respectively. Our working capital deficit is due to the fact that we received the CFDA approval for one product in April 2018 and we are in the process to produce, market and sell our product in China. We had no revenues during the period and that our sole source of financing is loans from our related parties and stockholders. Meanwhile, we have been upgrading our facilities and continuing R&D works.

Cash Flows

Net Cash Used in Operating Activities

Net cash used in operating activities was $601,678 and $331,618 in the nine months ended July 31, 2018 and 2017 respectively. This amount was attributable primarily to the net loss after adjustment for non-cash items, such as depreciation, loss on disposal of property and equipment, imputed interest on advances from directors, and others like charges in other receivables and prepaid expenses and other payables and accrued expenses.

Net Cash Used in Investing Activities

We recorded $50,386 net cash used and $1,202 net cash from in investing activities in the nine months ended July 31, 2018 and 2017 respectively. This amount reflected purchases of property and equipment, primarily for research and development to our facilities.

Net Cash Provided by Financing Activities

Net cash provided by financing activities in the nine months ended July 31, 2018 and 2017 was $660,919 and $333,370 respectively, which represented advances from a stockholder, directors and related parties, loan repayment to directors and advances to a related company.

Operating Capital and Capital Expenditure Requirements

Our ability to continue as a going concern and support the commercialization of current products is dependent upon our ability to market our product while obtaining additional financing in the near term. We anticipate that such funding will be in the form of equity financing from sales of our common stock. However, there is no assurance that we will be able to raise sufficient funding from the sale of our common stock to fund our business plan should we decide to proceed. We anticipate continuing to rely on advances from our related parties and stockholders in order to continue to fund our business operations.

We believe that our existing cash, cash equivalents at July 31, 2018, will be insufficient to meet our cash needs. Our minimum cash requirement for the next 12 months is projected to be $600,000. This amount may increase if we decide to start clinical trials on new products. Once we start production and marketing of our PA Screws, our revenue will cover our basic expenditures. Otherwise, we will continue to rely on external investments and shareholder’s loans to meet our cash needs. The management is actively pursuing additional funding and strategic partners, which will enable the Company to implement our business plan, business strategy, to continue research and development, clinical trials or further development that may arise.

We intend to spend more to support the commercialization of current products and on research and development activities, including new products development, regulatory and compliance, clinical studies, and the enhancement and protection of our intellectual property portfolio.

OFF-BALANCE SHEET ARRANGEMENTS

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to our investors.

CRITICAL ACCOUNTING POLICIES

The preparation of our financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates, including but not limited to those related to income taxes and impairment of long-lived assets. We base our estimates on historical experience and on various other assumptions and factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Based on our ongoing review, we plan to adjust to our judgments and estimates where facts and circumstances dictate. Actual results could differ from our estimates.

We believe the following critical accounting policies are important to the portrayal of our financial condition and results and require our management’s most difficult, subjective or complex judgments, often because of the need to make estimates about the effect of matters that are inherently uncertain.

Property and equipment

Property and equipment are stated at cost, less accumulated depreciation. Expenditures for additions, major renewals and betterments are capitalized and expenditures for maintenance and repairs are charged to expense as incurred.

Depreciation is provided on a straight-line basis, less estimated residual value over the assets estimated useful lives. The estimated useful lives of the assets are 5 years.

Long-lived assets

In accordance with FASB Codification Topic 360 (ASC Topic 360), “Accounting for the impairment or disposal of Long-Lived Assets”, long-lived assets and certain identifiable intangible assets held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. For purposes of evaluating the recoverability of long-lived assets, the recoverability test is performed using undiscounted net cash flows related to the long-lived assets. The Company reviews long-lived assets to determine that carrying values are not impaired.

Fair value of financial instruments

FASB Codification Topic 825 (ASC Topic 825), “Disclosure About Fair Value of Financial Instruments,” requires certain disclosures regarding the fair value of financial instruments. The carrying amounts of other receivables and prepaid expenses, other payables and accrued liabilities and due to a stockholder, directors and related parties approximate their fair values because of the short-term nature of the instruments. The management of the Company is of the opinion that the Company is not exposed to significant interest or credit risks arising from these financial statements.

Income taxes

The Company accounts for income taxes under The Financial Accounting Standards Board (FASB) Codification Topic 740-10-25 (“ASC 740-10-25”). Under ASC 740-10-25, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under ASC 740-10-25, the effect on deferred tax assets and liabilities of a change in tax rates is recognized as income in the period included the enactment date.

Research and Development

Research and development costs related to both present and future products are expensed as incurred.

Foreign currency translation

The reporting currency of the company’s financial statements is the US dollar. The financial statements of the Company’s subsidiary denominated in currencies other than the US dollar are translated into US dollars using the closing rate method. The balance sheet items are translated into US dollars using the exchange rates at the respective balance sheet dates. The capital and various reserves are translated at historical exchange rates prevailing at the time of the transactions while income and expenses items are translated at the average exchange rate for the year. All exchange differences are recorded within equity.

RECENT ACCOUNTING PRONOUNCEMENTS

Business Combination: Clarifying the Definition of a Business

Simplifying the Test for Goodwill Impairment

Share-based Compensation

In June 2018, the scope of Topic 718 has been expanded to include share-based payment transactions for acquiring goods and services from nonemployees. An entity should apply the requirements of Topic 718 to nonemployee awards except for specific guidance on inputs to an option pricing model and the attribution of cost (that is, the period of time over which share-based payment awards vest and the pattern of cost recognition over that period). The amendments specify that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. The amendments also clarify that Topic 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under Topic 606, Revenue from Contracts with Customers. The amendments in this Update are effective for public business entities for fiscal years beginning after December 15, 2018 and after December 15, 2019 for all other entities. Early adoption is permitted, but no earlier than an entity’s adoption date of Topic 606.

The Company does not anticipate that adoption of these guidance will have a material impact on its consolidated financial statements.

Revenue Recognition

Leases

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

We have established disclosure controls and procedures, as such term is defined in Rule 13a-15(e) under the Securities Exchange Act of 1934. Our disclosure controls and procedures are designed to ensure that material information relating to us, including our consolidated subsidiaries, is made known to our principal executive officer and principal financial officer by others within our organization. Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures as of July 31, 2018 to ensure that the information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act of 1934 is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act of 1934 is accumulated and communicated to our management, including our principal executive officer and principal financial officer as appropriate, to allow timely decisions regarding required disclosure. Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective as of July 31, 2018.

Changes in Internal Control

During the most recently completed fiscal quarter, there has been no change in the Company’s internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, its internal control over financial reporting.

PART II – OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

Currently we are not involved in any pending litigation or legal proceeding.

ITEM 1A. RISK FACTORS

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

None.

ITEM 6. EXHIBITS

The following documents are filed as a part of this report or are incorporated by reference to previous filings, if so indicated:

Exhibit No.		Description

3.1		Articles of Incorporation (1)
3.2		Bylaws (1)
31.1		Section 302 Certification of Chief Executive Officer*
31.2		Section 302 Certification of Chief Financial Officer *
32.1		Section 906 Certification of Chief Executive Officer *
32.2		Section 906 Certification of Chief Financial Officer *

101.INS		XBRL Instance Document
101.SCH		XBRL Taxonomy Extension Schema Document
101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF		XBRL Taxonomy Extension Definition Linkbase Document
101.LAB		XBRL Taxonomy Extension Label Linkbase Document
101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

*filed herewith

(1) Incorporated by reference to the Form SB-2 registration statement filed on January 16, 2007.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: September 19, 2018	By:
		ADVANCED BIOMEDICAL TECHNOLOGIES, INC.

		By:	/s/ Chi Ming Yu
			Chi Ming Yu, President and Director
			(Principal Executive Officer)

		By:	/s/ Hui Wang
			Hui Wang, Director and Chief Executive Officer
			(Controller)

		By:	/s/ Kai Gui
			Kai Gui, Director, Secretary and Chief Financial Officer
			(Principal Financial Officer)

EX-31.1 2 ex31-1.htm

Exhibit 31.1

SARBANES-OXLEY SECTION 302(a) CERTIFICATION

I, Hui Wang, certify that:

1.	I have reviewed this 10-Q for the three and nine months ended July 31, 2018 of Advanced BioMedical Technologies, Inc;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	a.	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b.	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c.	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d.	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	a.	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	b.	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: September 19, 2018	/s/ Hui Wang
	Hui Wang, Director and Chief Executive Officer

EX-31.2 3 ex31-2.htm

Exhibit 31.2

SARBANES-OXLEY SECTION 302(a) CERTIFICATION

I, Kai Gui, certify that:

1.	I have reviewed this 10-Q for the three and nine months ended July 31, 2018 of Advanced BioMedical Technologies, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	a.	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b.	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c.	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d.	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	a.	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	b.	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: September 19, 2018	/s/ Kai Gui
	Kai Gui, Director, Secretary, and Chief Financial Officer

EX-32.1 4 ex32-1.htm

Exhibit 32.1

CERTIFICATION PURSUANT TO
18 U.S.C. Section 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Advanced BioMedical Technologies, Inc. (the “Company”) on Form 10-Q for the period ended July 31, 2018, as filed with the Securities and Exchange Commission on the date hereof (the “report”), I, Hui Wang, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13 (a) or 15 (d) of the Securities Exchange Act of 1934; and

(2) The information contained in this Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: September 19, 2018

/s/ Hui Wang
Hui Wang, Director and Chief Executive Officer

EX-32.2 5 ex32-2.htm

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. Section 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Advanced BioMedical Technologies, Inc. (the “Company”) on Form 10-Q for the period ended July 31, 2018, as filed with the Securities and Exchange Commission on the date hereof (the “report”), I, Kai Gui, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in this Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: September 19, 2018

/s/ Kai Gui
Kai Gui, Director, Secretary, and Chief Financial Officer

EX-101.INS 6 abmt-20180731.xml XBRL INSTANCE FILE 0001385799 2017-11-01 2018-07-31 0001385799 2017-07-31 0001385799 2016-10-31 0001385799 2017-10-31 0001385799 us-gaap:CommonStockMember 2016-11-01 2017-10-31 0001385799 us-gaap:CommonStockMember 2016-10-31 0001385799 us-gaap:CommonStockMember 2017-10-31 0001385799 us-gaap:AdditionalPaidInCapitalMember 2016-11-01 2017-10-31 0001385799 us-gaap:AdditionalPaidInCapitalMember 2016-10-31 0001385799 us-gaap:AdditionalPaidInCapitalMember 2017-10-31 0001385799 us-gaap:RetainedEarningsMember 2016-11-01 2017-10-31 0001385799 us-gaap:RetainedEarningsMember 2016-10-31 0001385799 us-gaap:RetainedEarningsMember 2017-10-31 0001385799 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-11-01 2017-10-31 0001385799 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-10-31 0001385799 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-10-31 0001385799 ABMT:MasteriseMember srt:ParentCompanyMember 2008-12-30 2008-12-31 0001385799 ABMT:MasteriseMember 2007-05-30 2007-05-31 0001385799 ABMT:MasteriseMember srt:ParentCompanyMember 2008-12-31 0001385799 2018-07-31 0001385799 2016-11-01 2017-07-31 0001385799 us-gaap:CommonStockMember 2017-11-01 2018-07-31 0001385799 us-gaap:CommonStockMember 2018-07-31 0001385799 us-gaap:AdditionalPaidInCapitalMember 2017-11-01 2018-07-31 0001385799 us-gaap:AdditionalPaidInCapitalMember 2018-07-31 0001385799 us-gaap:RetainedEarningsMember 2017-11-01 2018-07-31 0001385799 us-gaap:RetainedEarningsMember 2018-07-31 0001385799 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-11-01 2018-07-31 0001385799 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-07-31 0001385799 2016-11-01 2017-10-31 0001385799 ABMT:ShenzhenChanghuaMember 2002-09-25 0001385799 ABMT:ShenzhenChanghuaMember 2002-09-24 2002-09-25 0001385799 ABMT:MasteriseMember ABMT:ShenzhenChanghuaMember 2008-01-29 0001385799 ABMT:MasteriseMember ABMT:ShenzhenChanghuaMember 2008-01-28 2008-01-29 0001385799 srt:ParentCompanyMember us-gaap:MajorityShareholderMember 2008-12-30 2008-12-31 0001385799 us-gaap:MajorityShareholderMember ABMT:MasteriseMember 2008-12-30 2008-12-31 0001385799 us-gaap:MajorityShareholderMember srt:ParentCompanyMember 2008-12-31 0001385799 ABMT:FourRelatedPartiesMember 2017-11-01 2018-07-31 0001385799 ABMT:FourRelatedPartiesMember 2016-11-01 2017-10-31 0001385799 2018-05-01 2018-07-31 0001385799 2017-05-01 2017-07-31 0001385799 2018-09-19 0001385799 ABMT:MasteriseMember ABMT:ShenzhenChanghuaMember 2007-05-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure Advanced Biomedical Technologies Inc. 0001385799 10-Q 2018-07-31 false --10-31 Smaller Reporting Company Q3 2018 69374850

0.00001

100000000

69374850

67124850

69374850

-4362295

-4995027

671

694

2520520

2673620

-6987698

-7679298

104212

9957

-5490370

694

2684923

-8326498

150511

2000000

99980

100000

250000

37497

37500

-647200

-691600

-507457

-647200

-691600

-215838

-170009

11303

15623

11303

15623

140554

-94255

140554

-94255

0.05

0.15

0.63

0.70

0.37

0.30

64100

1.00

0.70

0.807

0.70

50000

5000

5001000

4438250

724017

582795

684365

3767180

4212511

212902 169661 73063 57788 321420 301656

11303

11819

3662

3799

-7679298

-8326498

-647200

-507457

-215838

-170009

-601678

-331618

140554

-35905

357674

-101620

36892

35115

13166

7839

140554

-35905

357674

-101620

6771

12916

2254

4631

483482

488475

422967

419070

60515

69405

9629

6559

7463

15955

24932

34848

85447

130974

5080474

5621344

694

9957

150511

85447

130974

360769

244169

120799

74308

404432

292200

136219

86778

-404432

-292200

-136219

-86778

18590

25632

2900

18218

-242768

-215257

-79619

-83231

-647200

-507457

-215838

-170009

-506646

-543362

141836

-271629

-0.01

-0.00

69374850

67907818

69374850

1682

-1302

17686

-1202

-50386

1202

660919

333370

-363

116

8492

3070

5586496 ABMT

0.30

0.70

0.07

7055

10582

26721

8176

3441

4542

-32700

37500

3527

17469

18893

409079

422812

24588

112302

571636

302305

12823

40843

2673620

2684923

-102106 -71908

NOTE 1 BASIS OF PRESENTATION   The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.   In the opinion of management, the unaudited condensed consolidated financial statements contain adjustments considered necessary to present fairly the Company’s financial position as of July 31, 2018, the consolidated results of operations for the three and nine months ended July 31, 2018 and 2017 and consolidated statements of cash flows for the nine months ended July 31, 2018 and 2017 on an accrual basis and in accordance with accounting principles generally accepted in the United States of America for interim financial information and rules and regulations of the SEC. The consolidated results for the three and nine months ended July 31, 2018 are not necessarily indicative of the results to be expected for the entire fiscal year ending October 31, 2018. These consolidated financial statements should be read in conjunction with the consolidated financial statements and notes for the year ended October 31, 2017 appearing in the Company’s annual report on Form 10-K as filed with the Securities and Exchange Commission on February 13, 2018.   The reporting currency of the Company is US dollar.

NOTE 2 ORGANIZATION   Advanced BioMedical Technologies, Inc. (fka “Geostar Mineral Corporation” or “Geostar”) (“ABMT”) was incorporated in Nevada on September 12, 2006.   Shenzhen Changhua Biomedical Engineering Company Limited (“Shenzhen Changhua”) was incorporated in the People’s Republic of China (“PRC”) on September 25, 2002 as a limited liability company with a registered capital of $724,017. Shenzhen Changhua is owned by two stockholders in the proportion of 70% and 30% respectively. Shenzhen Changhua plans to develop, manufacture and market self-reinforced, re-absorbable degradable PA screws, robs and binding ties for fixation on human fractured bones. The Company is currently conducting clinical trials on its products and intends to raise additional capital to produce and market its products commercially pending the approval from the China Food and Drug Administration (“CFDA”, fka “SFDA”) of the PRC on its products. The Company has no revenue since its inception and, in accordance with Accounting Standards Codification (“ASC”) Topic 915, “Development Stage Entities” (formerly Statement of Financial Accounting Standard (“SFAS”) No. 7, “Accounting and Reporting by Development Stage Enterprise”), is considered a Development Stage Company.   Masterise Holdings Limited (“Masterise”) was incorporated in the British Virgin Islands on May 31, 2007 as an investment holding company and was then owned as to 63% by the spouse of Shenzhen Changhua’s 70% majority stockholder at the time and 37% by a third party corporation.   On January 29, 2008, Masterise entered into a Share Purchase Agreement (“the Agreement”) with a stockholder of Shenzhen Changhua whereupon Masterise acquired 70% of Shenzhen Changhua for US$64,100 in cash. The acquisition was completed on February 25, 2008. As both Masterise and Shenzhen Changhua were under common control and management, the acquisition was accounted for as a reorganization of entities under common control. Accordingly, the operations of Shenzhen Changhua were included in the consolidated financial statements as if the transactions had occurred retroactively.   On December 31, 2008, ABMT consummated a Share Exchange Agreement (“the Exchange Agreement”) with the stockholders of Masterise pursuant to which ABMT issued 50,000 shares of Common Stock to the stockholders of Masterise for 100% equity interest in Masterise.   Concurrently, on December 31, 2008, a major stockholder of ABMT also consummated an Affiliate Stock Purchase Agreement (the “Affiliate Agreement”) with thirteen individuals including all the stockholders of Masterise, pursuant to which the major stockholder sold a total of 5,001,000 shares of ABMT’s common stock for a total aggregate consideration of $5,000, including 4,438,250 shares to the stockholders of Masterise.   On consummation of the Exchange Agreement and the Affiliate Agreement, the 70% majority stockholder of Masterise became an 80.7% stockholder of ABMT.   On March 13, 2009, the name of the Company was changed from Geostar Mineral Corporation to Advanced Biomedical Technologies, Inc.   The merger of ABMT and Masterise was treated for accounting purposes as a capital transaction and recapitalization by Masterise (“the accounting acquirer”) and a re-organization by ABMT (“the accounting acquiree”). The financial statements have been prepared as if the re-organization had occurred retroactively.   Accordingly, these financial statements include the following:   <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 24px; font: 11pt/107% Calibri, Helvetica, Sans-Serif">(1)</td> <td style="font: 11pt/107% Calibri, Helvetica, Sans-Serif; text-align: justify">The balance sheet consisting of the net assets of the acquirer at historical cost and the net assets of the acquiree at historical cost.</td></tr> <tr style="vertical-align: top"> <td style="font: 11pt/107% Calibri, Helvetica, Sans-Serif"> </td> <td style="font: 11pt/107% Calibri, Helvetica, Sans-Serif"> </td> <td style="font: 11pt/107% Calibri, Helvetica, Sans-Serif; text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td style="font: 11pt/107% Calibri, Helvetica, Sans-Serif">(2)</td> <td style="font: 11pt/107% Calibri, Helvetica, Sans-Serif; text-align: justify">The statement of operations including the operations of the acquirer for the periods presented and the operations of the acquiree from the date of the transaction.</td></tr> </table>   ABMT, Masterise and Shenzhen Changhua are hereinafter referred to as (“the Company”).

NOTE 3 PRINCIPLES OF CONSOLIDATION   The accompanying condensed consolidated financial statements include the financial statements of ABMT and its wholly owned subsidiaries, Masterise and its 70% owned subsidiary, Shenzhen Changhua. The non-controlling interests in periods prior to 2012 represent the non-controlling stockholders’ 30% proportionate share of the results of Shenzhen Changhua.   All significant inter-company balances and transactions have been eliminated in consolidation. NOTE 4 USE OF ESTIMATES   The preparation of the financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

NOTE 5 RELATED PARTY TRANSACTIONS   As of July 31, 2018 and October 31, 2017, the Company owed a stockholder $684,365 and $582,795 respectively which are unsecured and repayable on demand. Interests are charged at 7% per annum on the amount owed.   As of July 31, 2018 and October 31, 2017, the Company owed four related parties a total of $4,212,511 and $3,767,180 respectively which are unsecured and repayable on demand. Interests are charged at 7% per annum on the amounts owed.    Total interest expenses on advances from a stockholder and the related parties accrued for the three and nine months ended July 31, 2018 and 2017 were $73,063, $57,788, $212,902, and $169,661 respectively.   As of July 31, 2018 and October 31, 2017, the Company owed $301,656 and $321,420 respectively, to two directors for advances made on an unsecured basis, repayable on demand and interest free.   Imputed interest charged at 5% per annum on the amounts owed to two directors is $3,662, $3,799, $11,303 and $11,819 for the three and nine months ended July 31, 2018 and 2017 respectively.

NOTE 6 COMMITMENTS AND CONTINGENCIES   The Company’s existing rental leases do not contain significant restrictive provisions. The schedule of future minimum lease obligations falling due under non-cancelable rental operating leases is as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 107%">Fiscal year ending October 31,</td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 82%; text-align: justify; line-height: 107%">2018</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 15%; text-align: right; line-height: 107%">3,527</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 107%">2019</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">7,055</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; text-align: justify; line-height: 107%">Total</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">10,582</td> <td style="line-height: 107%"> </td></tr> </table>

NOTE 7 FAIR VALUE OF FINANCIAL INSTRUMENTS   The Financial Accounting Standards Board (FASB) Codification Topic 825 (ASC Topic 825), “Disclosure About Fair Value of Financial Instruments,” requires certain disclosures regarding the fair value of financial instruments. The carrying amounts of other receivables and prepaid expenses, other payables and accrued liabilities and due to a stockholder, directors and related parties approximate their fair values because of the short-term nature of the instruments. The management of the Company is of the opinion that the Company is not exposed to significant interest or credit risks arising from these financial statements.

NOTE 8 RECENT ACCOUNTING PRONOUNCEMENTS   Business Combination: Clarifying the Definition of a Business   In January 2017, the FASB issued ASU No. 2017-1 “Topic 805, Business Combinations: Clarifying the Definition of a Business”. The amendments in this update provide a screen to determine when a set is not a business. The screen requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business. This screen reduces the number of transactions that need to be further evaluated. The amendments in this update affect all reporting entities that must determine whether they have acquired or sold a business. Public business entities should apply the amendments in this update to annual periods beginning after December 15, 2017, including interim periods within those periods. All other entities should apply the amendments to annual periods beginning after December 15, 2018, and interim periods within annual periods beginning after December 15, 2019. The Company does not expect the adoption of ASU 2017-1 to have a material impact on its consolidated financial statements.   Simplifying the Test for Goodwill Impairment   In January 2017, the FASB issued ASU No. 2017-4 “Topic 350: Intangibles-Goodwill and Other: Simplifying the Test for Goodwill Impairment.” The amendments in this update eliminate step two of the goodwill impairment test and specifies that goodwill impairment should be measured by comparing the fair value of a reporting unit with its carrying amount. Additionally, the amount of goodwill allocated to each reporting unit with a zero or negative carrying amount of net assets should be disclosed. The amendments in this update are effective for annual or interim goodwill impairment tests performed in fiscal years beginning after December 15, 2019; early adoption is permitted. The Company does not expect the adoption of ASU 2017-4 to have a material impact on its consolidated financial statements.  Share-based Compensation   In May 2017, the FASB issued guidance on changes to terms and conditions of share-based payment awards. The amendment provides guidance about which changes to terms or conditions of a share-based payment award require an entity to apply modification accounting. The guidance is effective for the fiscal year beginning on January 1, 2018, including interim periods within that year.   In June 2018, the scope of Topic 718 has been expanded to include sharebased payment transactions for acquiring goods and services from nonemployees. An entity should apply the requirements of Topic 718 to nonemployee awards except for specific guidance on inputs to an option pricing model and the attribution of cost (that is, the period of time over which share-based payment awards vest and the pattern of cost recognition over that period). The amendments specify that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. The amendments also clarify that Topic 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under Topic 606, Revenue from Contracts with Customers. The amendments in this Update are effective for public business entities for fiscal years beginning after December 15, 2018 and after December 15, 2019 for all other entities. Early adoption is permitted, but no earlier than an entity’s adoption date of Topic 606.   The Company does not anticipate that adoption of these guidances will have a material impact on its consolidated financial statements.   Revenue Recognition   In May 2014, the FASB issued guidance on revenue from contracts with customers that will supersede most current revenue recognition guidance, including industry-specific guidance. Under the new standard, a good or service is transferred to the customer when (or as) the customer obtains control of the good or service, which differs from the risk and rewards approach under current guidance. The guidance provides a five-step analysis of transactions to determine when and how revenue is recognized. Other major provisions include capitalization of certain contract costs, consideration of the time value of money in the transaction price and allowing estimates of variable consideration to be recognized before contingencies are resolved in certain circumstances. The guidance also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from an entity’s contracts with customers. In March, April and May 2016, the FASB issued three additional updates regarding identifying performance obligations and licensing, certain principal versus agent considerations and various narrow scope improvements based on practical questions raised by users. In September 2017, the FASB issued additional amendments providing clarification and implementation guidance. The guidance may be adopted through either retrospective application to all periods presented in the financial statements (full retrospective approach) or through a cumulative effect adjustment to retained earnings at the effective date (modified retrospective approach). The guidance is effective for the fiscal periods beginning on January 1, 2018.   Leases   In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) (“ASU 2016-02”), which modifies lease accounting for lessees to increase transparency and comparability by recording lease assets and liabilities for operating leases and disclosing key information about leasing arrangements. The new standard, as amended by ASU 2018-01 and ASU 2018-11, is effective for annual periods beginning after December 15, 2018 on a modified retrospective basis. The Company will adopt ASU 2016-02 in its first quarter of the year ending October 31 2020. The Company expects its leases designated as operating leases in Note 6, “Commitments and Contingencies,” will be reported on the consolidated balance sheets upon adoption. However, the ultimate impact of adopting ASU 2016-02 will depend on the lease terms as of the adoption date.   The Company has reviewed all recently issued, but not yet effective, accounting pronouncements and do not believe the future adoptions of any such pronouncements may be expected to cause a material impact on the financial condition or the results of operations.

NOTE 9 GOING CONCERN   As reflected in the accompanying unaudited condensed consolidated financial statements, the Company has not commenced revenue producing operations and has an accumulated deficit of $8,326,498 as of July 31, 2018 and which includes a net loss of $647,200 for the nine months ended July 31, 2018. As of July 31, 2018, the Company’s total current liabilities exceeded its total current assets by $5,586,496 and the Company used cash in operations of $601,678 for the nine months ended on that date. These factors raise substantial doubt about its ability to continue as a going concern. In view of the matters described above, recoverability of a major portion of the recorded asset amounts shown in the accompanying condensed consolidated balance sheet is dependent upon continued operations of the Company, which in turn is dependent upon the Company’s ability to raise additional capital, obtain financing and succeed in its future operations. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.   Management has taken the following steps to revise its operating and financial requirements, which it believes are sufficient to provide the Company with the ability to continue as a going concern. The Company is actively pursuing additional funding and strategic partners, which will enable the Company to implement its business plan. Management believes that these actions as successful will allow the Company to continue its operations through the next fiscal year.

The schedule of future minimum lease obligations falling due under non-cancelable rental operating leases is as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 107%">Fiscal year ending October 31,</td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 82%; text-align: justify; line-height: 107%">2018</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 15%; text-align: right; line-height: 107%">3,527</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 107%">2019</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">7,055</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; text-align: justify; line-height: 107%">Total</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">10,582</td> <td style="line-height: 107%"> </td></tr> </table>

EX-101.SCH 7 abmt-20180731.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statements of Stockholders' Deficit (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Consolidated Statements of Stockholders' Deficit (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Organization link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Principles of Consolidation link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Use of Estimates link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Fair Value of Financial Instruments link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Recent Accounting Pronouncements link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Going Concern link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Organization (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Principles of Consolidation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Lease Obligations of Operating Leases (Details) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Going Concern (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 abmt-20180731_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 abmt-20180731_def.xml XBRL DEFINITION FILE EX-101.LAB 10 abmt-20180731_lab.xml XBRL LABEL FILE Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Accumulated Deficit [Member] Accumulated Other Comprehensive Loss [Member] Investment, Name [Axis] Masterise [Member] Consolidated Entities [Axis] ABMT [Member] Related Party Transaction [Axis] Shenzhen Changhua [Member] Majority Shareholders [Member] Four Related Parties [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Filer Category Entity Common Stock, Shares Outstanding Trading Symbol Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS CURRENT ASSETS Cash and cash equivalents Other receivables and prepaid expenses Total Current Assets Property and equipment, cost Less: Accumulated depreciation PROPERTY AND EQUIPMENT, NET LONG-TERM PREPAID EXPENSES, NET TOTAL ASSETS LIABILITIES AND STOCKHOLDERS' DEFICIT CURRENT LIABILITIES Other payables and accrued expenses Due to directors Due to a stockholder Due to related parties Total Current Liabilities STOCKHOLDERS' DEFICIT Common stock, $0.00001 par value, 100,000,000 shares authorized, 69,374,850 issued and outstanding as of July 31, 2018 and October 31, 2017 Additional paid-in capital Accumulated deficit Accumulated other comprehensive income/(loss) Total Deficit TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] OPERATING EXPENSES General and administrative expenses Depreciation Research and development Total Operating Expenses LOSS FROM OPERATIONS OTHER (EXPENSES) INCOME Interest income Interest paid to a stockholder and related parties Interest paid to a third party Imputed interest Other, net Total Other (Expenses) Income, net LOSS BEFORE TAXES Income tax expense NET LOSS Net loss attributable to non-controlling interests NET LOSS ATTRIBUTABLE TO ABMT COMMON STOCKHOLDERS OTHER COMPREHENSIVE INCOME Foreign currency translation income Total other comprehensive gain/(loss) COMPREHENSIVE GAIN/(LOSS) ATTRIBUTABLE TO ABMT COMMON STOCKHOLDERS Net loss per share-basic and diluted - basic and diluted Weighted average number of shares outstanding during the period - basic and diluted Statement [Table] Statement [Line Items] Balance Balance, shares Stock issued for debt conversion at 0.05 per share Stock issued for debt conversion at 0.05 per share, shares Stock issued for services ($0.15 per share) Stock issued for services ($0.15 per share), shares Imputed interest on advances from directors Net loss for the period Foreign currency translation loss Balance Balance, shares Statement of Stockholders' Equity [Abstract] Debt conversion price, per share Shares issued for service, per share Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Net loss attributable to ABMT common stockholders Adjustments to reconcile net loss to cash used in Amortisation of long-term prepaid expenses Stock issued for services Imputed interest Changes in operating assets and liabilities Decrease (increase) in: Other receivables and prepaid expenses Increase in: Other payables and accrued expenses Net cash used in operating activities CASH FLOWS FROM INVESTING ACTIVITIES Purchase of property and equipment Renovation of factory premises (Increase) decrease in deposit for purchase of property and equipment Net cash used in investing activities CASH FLOWS FROM FINANCING ACTIVITIES Due to a stockholder Due to directors Due to related parties Net cash provided by financing activities EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS NET INCREASE IN CASH AND CASH EQUIVALENTS CASH AND CASH EQUIVALENTS AT THE BEGINNING OF PERIOD CASH AND CASH EQUIVALENTS AT THE END OF PERIOD Accounting Policies [Abstract] Basis of Presentation Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization Principles of Consolidation Use Of Estimates Use of Estimates Related Party Transactions [Abstract] Related Party Transactions Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Fair Value Disclosures [Abstract] Fair Value of Financial Instruments Accounting Changes and Error Corrections [Abstract] Recent Accounting Pronouncements Going Concern Schedule of Future Minimum Lease Obligations of Operating Leases Registered capital Ownership interest - majority stockholder Ownership interest - minority stockholder Ownership acquired Payment for acquisition Stock issued in acquisition, shares Stock sold per affiliate agreement, shares Stock sold per affiliate agreement Ownership of subsidiaries Ownership by noncontrolling stockholders Related Party [Axis] Due to stockholder Interest rate Interest paid to a stockholder and related parties Fiscal year ending October 31, 2018 Fiscal year ending October 31, 2019 Total Accumulated deficit Net loss Working capital deficit Net cash used in operating activities The financial statement for which currency rates are applied in computing translation adjustments.. Chen Tie Jun [Member] Chi Ming Yu [Member] Information about related party. Person serving on the board of directors (who collectively have responsibility for governing the entity). Person serving on the board of directors (who collectively have responsibility for governing the entity). Lease arrangements by type. Carrying amount as of the balance sheet date of obligations due stockholders. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer). Hui Wang [Member] The financial statements for which currency rates are applied in computing translation adjustments.. Interest paid to a stockholder and related parties. Masterise Holdings Limited [Member] Name of investment. Mr. Chi Ming Yu and Kai Gui [Member] Office Space [Member] P.R.C [Member] Principles of consolidation [Text Block] Que Feng [Member] Related Parties [Member] Shenzhen Changhua Biomedical Engineering Company Limited [Member] Shenzhen Changhua [Member] Shenzhen Hygeian Medical Device Co., Ltd. [Member] Stockholder and Related Parties [Member] Stockholder [Member] Titan Technology Development Limited, a Stockholder [Member] Titan Technology Development Ltd - Stockholder [Member] Two Directors [Member] Two Related Parties [Member] United States [Member] Use of estimates [Text Block] Wang Hui [Member] Working capital deficit. Yu Chi Fung [Member] Three Related Parties [Member] Renovation of factory premises. Repayments to officer or stockholders. Four Related Parties [Member] Assets, Current Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property, Plant and Equipment, Net Assets Liabilities, Current Stockholders' Equity Attributable to Parent Liabilities and Equity Operating Expenses Operating Income (Loss) Interest Expense, Other Other Nonoperating Expense EX-101.PRE 11 abmt-20180731_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Jul. 31, 2018	Sep. 19, 2018
Document And Entity Information
Entity Registrant Name	Advanced Biomedical Technologies Inc.
Entity Central Index Key	0001385799
Document Type	10-Q
Document Period End Date	Jul. 31, 2018
Amendment Flag	false
Current Fiscal Year End Date	--10-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		69,374,850
Trading Symbol	ABMT
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2018

XML 13 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets - USD ($)	Jul. 31, 2018	Oct. 31, 2017
CURRENT ASSETS
Cash and cash equivalents	$ 15,955	$ 7,463
Other receivables and prepaid expenses	18,893	17,469
Total Current Assets	34,848	24,932
Property and equipment, cost	488,475	483,482
Less: Accumulated depreciation	(419,070)	(422,967)
PROPERTY AND EQUIPMENT, NET	69,405	60,515
LONG-TERM PREPAID EXPENSES, NET	26,721
TOTAL ASSETS	130,974	85,447
CURRENT LIABILITIES
Other payables and accrued expenses	422,812	409,079
Due to directors	301,656	321,420
Due to a stockholder	684,365	582,795
Due to related parties	4,212,511	3,767,180
Total Current Liabilities	5,621,344	5,080,474
STOCKHOLDERS' DEFICIT
Common stock, $0.00001 par value, 100,000,000 shares authorized, 69,374,850 issued and outstanding as of July 31, 2018 and October 31, 2017	694	694
Additional paid-in capital	2,684,923	2,673,620
Accumulated deficit	(8,326,498)	(7,679,298)
Accumulated other comprehensive income/(loss)	150,511	9,957
Total Deficit	(5,490,370)	(4,995,027)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 130,974	$ 85,447

XML 14 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jul. 31, 2018	Oct. 31, 2017
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.00001	$ 0.00001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	69,374,850	69,374,850
Common stock, shares outstanding	69,374,850	69,374,850

XML 15 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Jul. 31, 2018	Jul. 31, 2017	Jul. 31, 2018	Jul. 31, 2017
OPERATING EXPENSES
General and administrative expenses	$ 120,799	$ 74,308	$ 360,769	$ 244,169
Depreciation	2,254	4,631	6,771	12,916
Research and development	13,166	7,839	36,892	35,115
Total Operating Expenses	136,219	86,778	404,432	292,200
LOSS FROM OPERATIONS	(136,219)	(86,778)	(404,432)	(292,200)
OTHER (EXPENSES) INCOME
Interest income	6	15	27	31
Interest paid to a stockholder and related parties	(73,063)	(57,788)	(212,902)	(169,661)
Interest paid to a third party		(3,441)		(8,176)
Imputed interest	(3,662)	(3,799)	(11,303)	(11,819)
Other, net	(2,900)	(18,218)	(18,590)	(25,632)
Total Other (Expenses) Income, net	(79,619)	(83,231)	(242,768)	(215,257)
LOSS BEFORE TAXES	(215,838)	(170,009)	(647,200)	(507,457)
Income tax expense
NET LOSS	(215,838)	(170,009)	(647,200)	(507,457)
Net loss attributable to non-controlling interests
NET LOSS ATTRIBUTABLE TO ABMT COMMON STOCKHOLDERS	(215,838)	(170,009)	(647,200)	(507,457)
OTHER COMPREHENSIVE INCOME
Foreign currency translation income	357,674	(101,620)	140,554	(35,905)
Total other comprehensive gain/(loss)	357,674	(101,620)	140,554	(35,905)
COMPREHENSIVE GAIN/(LOSS) ATTRIBUTABLE TO ABMT COMMON STOCKHOLDERS	$ 141,836	$ (271,629)	$ (506,646)	$ (543,362)
Net loss per share-basic and diluted - basic and diluted	$ (0.00)	$ (0.00)	$ (0.01)	$ (0.01)
Weighted average number of shares outstanding during the period - basic and diluted	69,374,850	69,374,850	69,374,850	67,907,818

XML 16 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Stockholders' Deficit (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Loss [Member]	Total
Balance at Oct. 31, 2016	$ 671	$ 2,520,520	$ (6,987,698)	$ 104,212	$ (4,362,295)
Balance, shares at Oct. 31, 2016	67,124,850
Stock issued for debt conversion at 0.05 per share	$ 20	99,980			100,000
Stock issued for debt conversion at 0.05 per share, shares	2,000,000
Stock issued for services ($0.15 per share)	$ 3	37,497			37,500
Stock issued for services ($0.15 per share), shares	250,000
Imputed interest on advances from directors		15,623			15,623
Net loss for the period			(691,600)		(691,600)
Foreign currency translation loss				(94,255)	(94,255)
Balance at Oct. 31, 2017	$ 694	2,673,620	(7,679,298)	9,957	(4,995,027)
Balance, shares at Oct. 31, 2017	69,374,850
Imputed interest on advances from directors		11,303			11,303
Net loss for the period			(647,200)		(647,200)
Foreign currency translation loss				140,554	140,554
Balance at Jul. 31, 2018	$ 694	$ 2,684,923	$ (8,326,498)	$ 150,511	$ (5,490,370)
Balance, shares at Jul. 31, 2018	69,374,850

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

XML 17 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Stockholders' Deficit (Unaudited) (Parenthetical)	Oct. 31, 2017 $ / shares
Statement of Stockholders' Equity [Abstract]
Debt conversion price, per share	$ 0.05
Shares issued for service, per share	$ 0.15

XML 18 R7.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Jul. 31, 2018	Jul. 31, 2017
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss attributable to ABMT common stockholders	$ (647,200)	$ (507,457)
Adjustments to reconcile net loss to cash used in
Depreciation	6,771	12,916
Amortisation of long-term prepaid expenses	4,542
Stock issued for services		37,500
Imputed interest	11,303	11,819
Decrease (increase) in:
Other receivables and prepaid expenses	(1,682)	1,302
Increase in:
Other payables and accrued expenses	24,588	112,302
Net cash used in operating activities	(601,678)	(331,618)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property and equipment	(17,686)
Renovation of factory premises	(32,700)
(Increase) decrease in deposit for purchase of property and equipment		1,202
Net cash used in investing activities	(50,386)	1,202
CASH FLOWS FROM FINANCING ACTIVITIES
Due to a stockholder	102,106	71,908
Due to directors	(12,823)	(40,843)
Due to related parties	571,636	302,305
Net cash provided by financing activities	660,919	333,370
EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS	(363)	116
NET INCREASE IN CASH AND CASH EQUIVALENTS	8,492	3,070
CASH AND CASH EQUIVALENTS AT THE BEGINNING OF PERIOD	7,463	6,559
CASH AND CASH EQUIVALENTS AT THE END OF PERIOD	$ 15,955	$ 9,629

XML 19 R8.htm IDEA: XBRL DOCUMENT

Basis of Presentation

9 Months Ended

Jul. 31, 2018

Accounting Policies [Abstract]

Basis of Presentation

NOTE 1 BASIS OF PRESENTATION

The reporting currency of the Company is US dollar.

XML 20 R9.htm IDEA: XBRL DOCUMENT

Organization

9 Months Ended

Jul. 31, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization

NOTE 2 ORGANIZATION

Advanced BioMedical Technologies, Inc. (fka “Geostar Mineral Corporation” or “Geostar”) (“ABMT”) was incorporated in Nevada on September 12, 2006.

On consummation of the Exchange Agreement and the Affiliate Agreement, the 70% majority stockholder of Masterise became an 80.7% stockholder of ABMT.

On March 13, 2009, the name of the Company was changed from Geostar Mineral Corporation to Advanced Biomedical Technologies, Inc.

Accordingly, these financial statements include the following:

	(1)	The balance sheet consisting of the net assets of the acquirer at historical cost and the net assets of the acquiree at historical cost.

	(2)	The statement of operations including the operations of the acquirer for the periods presented and the operations of the acquiree from the date of the transaction.

ABMT, Masterise and Shenzhen Changhua are hereinafter referred to as (“the Company”).

XML 21 R10.htm IDEA: XBRL DOCUMENT

Principles of Consolidation

9 Months Ended

Jul. 31, 2018

Accounting Policies [Abstract]

Principles of Consolidation

NOTE 3 PRINCIPLES OF CONSOLIDATION

All significant inter-company balances and transactions have been eliminated in consolidation.

XML 22 R11.htm IDEA: XBRL DOCUMENT

Use of Estimates

9 Months Ended

Jul. 31, 2018

Use Of Estimates

Use of Estimates

NOTE 4 USE OF ESTIMATES

XML 23 R12.htm IDEA: XBRL DOCUMENT

Related Party Transactions

9 Months Ended

Jul. 31, 2018

Related Party Transactions

NOTE 5 RELATED PARTY TRANSACTIONS

As of July 31, 2018 and October 31, 2017, the Company owed $301,656 and $321,420 respectively, to two directors for advances made on an unsecured basis, repayable on demand and interest free.

Imputed interest charged at 5% per annum on the amounts owed to two directors is $3,662, $3,799, $11,303 and $11,819 for the three and nine months ended July 31, 2018 and 2017 respectively.

XML 24 R13.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

9 Months Ended

Jul. 31, 2018

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

NOTE 6 COMMITMENTS AND CONTINGENCIES

Fiscal year ending October 31,
2018		3,527
2019		7,055

Total	$	10,582

XML 25 R14.htm IDEA: XBRL DOCUMENT

Fair Value of Financial Instruments

9 Months Ended

Jul. 31, 2018

Fair Value Disclosures [Abstract]

Fair Value of Financial Instruments

NOTE 7 FAIR VALUE OF FINANCIAL INSTRUMENTS

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 26 R15.htm IDEA: XBRL DOCUMENT

Recent Accounting Pronouncements

9 Months Ended

Jul. 31, 2018

Accounting Changes and Error Corrections [Abstract]

Recent Accounting Pronouncements

NOTE 8 RECENT ACCOUNTING PRONOUNCEMENTS

Business Combination: Clarifying the Definition of a Business

Simplifying the Test for Goodwill Impairment

Share-based Compensation

The Company does not anticipate that adoption of these guidances will have a material impact on its consolidated financial statements.

Revenue Recognition

Leases

XML 27 R16.htm IDEA: XBRL DOCUMENT

Going Concern

9 Months Ended

Jul. 31, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Going Concern

NOTE 9 GOING CONCERN

XML 28 R17.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Tables)

9 Months Ended

Jul. 31, 2018

Commitments and Contingencies Disclosure [Abstract]

Schedule of Future Minimum Lease Obligations of Operating Leases

The schedule of future minimum lease obligations falling due under non-cancelable rental operating leases is as follows:

Fiscal year ending October 31,
2018		3,527
2019		7,055

Total	$	10,582

XML 29 R18.htm IDEA: XBRL DOCUMENT

Organization (Details Narrative) - USD ($)	Dec. 31, 2008	Jan. 29, 2008	May 31, 2007	Sep. 25, 2002
Masterise [Member]
Ownership interest - majority stockholder			63.00%
Ownership interest - minority stockholder			37.00%
Masterise [Member] \| ABMT [Member]
Ownership acquired	100.00%
Stock issued in acquisition, shares	50,000
Shenzhen Changhua [Member]
Registered capital				$ 724,017
Ownership interest - majority stockholder				70.00%
Ownership interest - minority stockholder				30.00%
Shenzhen Changhua [Member] \| Masterise [Member]
Ownership acquired		70.00%	70.00%
Payment for acquisition		$ 64,100
Majority Shareholders [Member] \| ABMT [Member]
Ownership acquired	80.70%
Stock sold per affiliate agreement, shares	5,001,000
Stock sold per affiliate agreement	$ 5,000
Majority Shareholders [Member] \| Masterise [Member]
Ownership interest - majority stockholder	70.00%
Stock sold per affiliate agreement, shares	4,438,250

XML 30 R19.htm IDEA: XBRL DOCUMENT

Principles of Consolidation (Details Narrative)	Jul. 31, 2018
Accounting Policies [Abstract]
Ownership of subsidiaries	70.00%
Ownership by noncontrolling stockholders	30.00%

XML 31 R20.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Jul. 31, 2018	Jul. 31, 2017	Jul. 31, 2018	Jul. 31, 2017	Oct. 31, 2017
Due to stockholder	$ 684,365		$ 684,365		$ 582,795
Interest rate			7.00%		7.00%
Due to related parties	4,212,511		$ 4,212,511		$ 3,767,180
Interest paid to a stockholder and related parties	73,063	$ 57,788	212,902	$ 169,661
Due to directors	301,656		301,656		$ 321,420
Imputed interest	$ 3,662	$ 3,799	$ 11,303	$ 11,819
Four Related Parties [Member]
Interest rate			7.00%		7.00%

XML 32 R21.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Schedule of Future Minimum Lease Obligations of Operating Leases (Details)	Jul. 31, 2018 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Fiscal year ending October 31, 2018	$ 3,527
Fiscal year ending October 31, 2019	7,055
Total	$ 10,582

XML 33 R22.htm IDEA: XBRL DOCUMENT

Going Concern (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
Going Concern (Details Narrative) - USD ($)	Jul. 31, 2018	Jul. 31, 2017	Jul. 31, 2018	Jul. 31, 2017	Oct. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated deficit	$ 8,326,498		$ 8,326,498		$ 7,679,298
Net loss	215,838	$ 170,009	647,200	$ 507,457
Working capital deficit	$ 5,586,496		5,586,496
Net cash used in operating activities			$ 601,678	$ 331,618

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=84234705&loc=SL4591551-111686

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3000-108585

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=84234705&loc=SL4591552-111686

+ Details

EXCEL 34 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 35 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 36 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 38 FilingSummary.xml IDEA: XBRL DOCUMENT 3.10.0.1 html 43 104 1 false 9 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://advbiomed.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets Sheet http://advbiomed.com/role/BalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://advbiomed.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Sheet http://advbiomed.com/role/StatementsOfOperationsAndComprehensiveLoss Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statements of Stockholders' Deficit (Unaudited) Sheet http://advbiomed.com/role/StatementsOfStockholdersDeficit Condensed Consolidated Statements of Stockholders' Deficit (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Consolidated Statements of Stockholders' Deficit (Unaudited) (Parenthetical) Sheet http://advbiomed.com/role/StatementsOfStockholdersDeficitParenthetical Condensed Consolidated Statements of Stockholders' Deficit (Unaudited) (Parenthetical) Statements 6 false false R7.htm 00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://advbiomed.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 7 false false R8.htm 00000008 - Disclosure - Basis of Presentation Sheet http://advbiomed.com/role/BasisOfPresentation Basis of Presentation Notes 8 false false R9.htm 00000009 - Disclosure - Organization Sheet http://advbiomed.com/role/Organization Organization Notes 9 false false R10.htm 00000010 - Disclosure - Principles of Consolidation Sheet http://advbiomed.com/role/PrinciplesOfConsolidation Principles of Consolidation Notes 10 false false R11.htm 00000011 - Disclosure - Use of Estimates Sheet http://advbiomed.com/role/UseOfEstimates Use of Estimates Notes 11 false false R12.htm 00000012 - Disclosure - Related Party Transactions Sheet http://advbiomed.com/role/RelatedPartyTransactions Related Party Transactions Notes 12 false false R13.htm 00000013 - Disclosure - Commitments and Contingencies Sheet http://advbiomed.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 13 false false R14.htm 00000014 - Disclosure - Fair Value of Financial Instruments Sheet http://advbiomed.com/role/FairValueOfFinancialInstruments Fair Value of Financial Instruments Notes 14 false false R15.htm 00000015 - Disclosure - Recent Accounting Pronouncements Sheet http://advbiomed.com/role/RecentAccountingPronouncements Recent Accounting Pronouncements Notes 15 false false R16.htm 00000016 - Disclosure - Going Concern Sheet http://advbiomed.com/role/GoingConcern Going Concern Notes 16 false false R17.htm 00000017 - Disclosure - Commitments and Contingencies (Tables) Sheet http://advbiomed.com/role/CommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://advbiomed.com/role/CommitmentsAndContingencies 17 false false R18.htm 00000018 - Disclosure - Organization (Details Narrative) Sheet http://advbiomed.com/role/OrganizationDetailsNarrative Organization (Details Narrative) Details http://advbiomed.com/role/Organization 18 false false R19.htm 00000019 - Disclosure - Principles of Consolidation (Details Narrative) Sheet http://advbiomed.com/role/PrinciplesOfConsolidationDetailsNarrative Principles of Consolidation (Details Narrative) Details http://advbiomed.com/role/PrinciplesOfConsolidation 19 false false R20.htm 00000020 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://advbiomed.com/role/RelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) Details http://advbiomed.com/role/RelatedPartyTransactions 20 false false R21.htm 00000021 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Lease Obligations of Operating Leases (Details) Sheet http://advbiomed.com/role/CommitmentsAndContingencies-ScheduleOfFutureMinimumLeaseObligationsOfOperatingLeasesDetails Commitments and Contingencies - Schedule of Future Minimum Lease Obligations of Operating Leases (Details) Details 21 false false R22.htm 00000022 - Disclosure - Going Concern (Details Narrative) Sheet http://advbiomed.com/role/GoingConcernDetailsNarrative Going Concern (Details Narrative) Details http://advbiomed.com/role/GoingConcern 22 false false All Reports Book All Reports abmt-20180731.xml abmt-20180731.xsd abmt-20180731_cal.xml abmt-20180731_def.xml abmt-20180731_lab.xml abmt-20180731_pre.xml http://fasb.org/srt/2018-01-31 http://xbrl.sec.gov/dei/2018-01-31 http://fasb.org/us-gaap/2018-01-31 true true ZIP 40 0001493152-18-013468-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-18-013468-xbrl.zip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end